Genetic analysis of familial hypercholesterolaemia in Western Australia

Atherosclerosis

Volumn 224, Issue 2, 2012, Pages 430-434

  Hooper, Amanda J ^a,b,c   Nguyen, Lan T ^a   Burnett, John R ^a,b,c   Bates, Timothy R ^a,b   Bell, Damon A ^a,b   Redgrave, Trevor G ^a   Watts, Gerald F ^a,b   van Bockxmeer, Frank M ^a,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Familial hypercholesterolaemia; LDL receptor; Mutations

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; AUSTRALIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; GENE DUPLICATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INTRONS; MUTATION; PHENOTYPE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RNA SPLICE SITES; SEQUENCE DELETION; SERINE ENDOPEPTIDASES; WESTERN AUSTRALIA;

EID: 84866564804     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.07.030     Document Type: Article

References (24)

1. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The metabolic and molecular bases of inherited disease 2001, 2863-2913. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
2. Burnett J.R., Hooper A.J. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev 2008, 29:11-26.
3. Yuan G., Wang J., Hegele R.A. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006, 174:1124-1129.
4. World Health Organization. Familial hypercholesterolemia. Report of a second WHO consultation. WHO/HGN/FH/CONS/99.2. 1999.
5. UCL LDLR Database. [accessed 20.04.12]. http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/.
6. Humphries S.E., Norbury G., Leigh S., Hadfield S.G., Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia?. Curr Opin Lipidol 2008, 19:362-368.
7. Liyanage K.E., Burnett J.R., Hooper A.J., van Bockxmeer F.M. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci 2011, 48:1-18.
8. Burnett J.R., Ravine D., van Bockxmeer F.M., Watts G.F. Familial hypercholesterolaemia: a look back, a look ahead. Med J Aust 2005, 182:552-553.
9. Leren T.P., Finborud T.H., Manshaus T.E., Ose L., Berge K.E. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008, 11:26-35.
10. Watts G.F., van Bockxmeer F.M., Bates T., Burnett J.R., Juniper A., O'Leary P. A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. Heart Lung Circ 2010, 19:419-422.
11. Familial Hypercholesterolaemia Western Australia Program Committee Model of care - familial hypercholesterolaemia August 2008, [accessed 20.04.12]. http://www.genomics.health.wa.gov.au/fh/docs/FH_Model_of_care.pdf.
12. Watts G.F., Sullivan D.R., Poplawski N., et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011, 12:221-263.
13. Leren T.P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004, 65:419-422.
14. Adzhubei I.A., Schmidt S., Peshkin L., et al. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
15. Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081.
16. Schwarz J.M., Rodelsperger C., Schuelke M., Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010, 7:575-576.
17. Francova H., Trbusek M., Zapletalova P., Kuhrova V. New promoter mutations in the low-density lipoprotein receptor gene which induce familial hypercholesterolaemia phenotype: molecular and functional analysis. J Inherit Metab Dis 2004, 27:523-528.
18. Marduel M., Carrie A., Sassolas A., et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat 2010, 31:E1811-E1824.
19. Taylor A., Wang D., Patel K., et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010, 77:572-580.
20. Naoumova R.P., Tosi I., Patel D., et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005, 25:2654-2660.
21. Humphries S.E., Cranston T., Allen M., et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med 2006, 84:203-214.
22. Junyent M., Gilabert R., Zambon D., et al. Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. Arterioscler Thromb Vasc Biol 2008, 28:580-586.
23. de Graaf J., van der Vleuten G., Stalenhoef A.F. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 2004, 4:229-240.
24. Soria L.F., Ludwig E.H., Clarke H.R., Vega G.L., Grundy S.M., McCarthy B.J. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989, 86:587-591.